WO2012015168A3 - 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 - Google Patents

로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 Download PDF

Info

Publication number
WO2012015168A3
WO2012015168A3 PCT/KR2011/004539 KR2011004539W WO2012015168A3 WO 2012015168 A3 WO2012015168 A3 WO 2012015168A3 KR 2011004539 W KR2011004539 W KR 2011004539W WO 2012015168 A3 WO2012015168 A3 WO 2012015168A3
Authority
WO
WIPO (PCT)
Prior art keywords
rosuvastatin
pharmaceutically acceptable
acceptable salt
pharmaceutical composition
composition
Prior art date
Application number
PCT/KR2011/004539
Other languages
English (en)
French (fr)
Other versions
WO2012015168A2 (ko
Inventor
전일순
손수경
전은경
채강수
오미화
최용환
이윤정
백승희
홍주용
Original Assignee
씨제이제일제당 (주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 씨제이제일제당 (주) filed Critical 씨제이제일제당 (주)
Publication of WO2012015168A2 publication Critical patent/WO2012015168A2/ko
Publication of WO2012015168A3 publication Critical patent/WO2012015168A3/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

본 발명은 로수바스타틴 또는 이의 약학적 허용염 및 안정화제로서 무수인산수소칼슘을 포함하는 약학 조성물을 제공한다. 본 발명의 조성물은 우수한 저장 안정성을 가진다.
PCT/KR2011/004539 2010-07-28 2011-06-22 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물 WO2012015168A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100072793A KR101302243B1 (ko) 2010-07-28 2010-07-28 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물
KR10-2010-0072793 2010-07-28

Publications (2)

Publication Number Publication Date
WO2012015168A2 WO2012015168A2 (ko) 2012-02-02
WO2012015168A3 true WO2012015168A3 (ko) 2012-04-19

Family

ID=45530558

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/004539 WO2012015168A2 (ko) 2010-07-28 2011-06-22 로수바스타틴 또는 이의 약학적 허용염을 포함하는 약학 조성물

Country Status (2)

Country Link
KR (1) KR101302243B1 (ko)
WO (1) WO2012015168A2 (ko)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6384992B2 (ja) * 2014-08-26 2018-09-05 ダイト株式会社 ロスバスタチンカルシウムの安定性を向上させた保存方法
KR101875112B1 (ko) * 2015-07-08 2018-07-09 씨제이헬스케어 주식회사 암로디핀, 발사르탄 및 로수바스타틴을 포함하는 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050045993A (ko) * 2002-07-26 2005-05-17 머크 샤프 앤드 돔 리미티드 콜레스테롤 흡수 억제제, ＨＭＧ-ＣｏＡ 리덕타제 억제제및 안정화제를 포함하는 조성물
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
US20080249120A1 (en) * 2006-11-22 2008-10-09 Glenmark Pharmaceuticals Limited Pharmaceutical compositions
KR20100063672A (ko) * 2008-12-03 2010-06-11 동아제약주식회사 에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2508840A1 (en) * 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
BRPI0606883A2 (pt) * 2005-02-10 2009-12-01 Lifecycle Pharma As composição farmacêutica para administração oral, método para preparar um tablete, e, forma de dosagem sólida única

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20050045993A (ko) * 2002-07-26 2005-05-17 머크 샤프 앤드 돔 리미티드 콜레스테롤 흡수 억제제, ＨＭＧ-ＣｏＡ 리덕타제 억제제및 안정화제를 포함하는 조성물
KR20060085682A (ko) * 2003-10-10 2006-07-27 라이프사이클 파마 에이/에스 피브레이트 및 스타틴을 함유하는 고형 제제
US20080249120A1 (en) * 2006-11-22 2008-10-09 Glenmark Pharmaceuticals Limited Pharmaceutical compositions
KR20100063672A (ko) * 2008-12-03 2010-06-11 동아제약주식회사 에이취엠지-코에이 환원효소 억제제를 함유하는 안정한 약제학적 조성물

Also Published As

Publication number Publication date
KR20120011158A (ko) 2012-02-07
KR101302243B1 (ko) 2013-09-02
WO2012015168A2 (ko) 2012-02-02

Similar Documents

Publication Publication Date Title
PH12015500064B1 (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
MY163083A (en) Solid forms of a pharmaceutically active substance
UA105229C2 (uk) Фармацевтичний склад
WO2012021715A3 (en) Stable formulations of linaclotide
WO2013082345A8 (en) Aryl dihydropyridinones and piperidinones as mgat2 inhibitors
WO2012020131A3 (en) Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2011157721A3 (en) Ivabradine-containing pharmaceutical composition
MY187718A (en) Pharmaceutical formulations
WO2012065057A3 (en) Phosphatidylinositol 3-kinase inhibitors and methods of their use
MX2013004190A (es) Composiciones y metodos para el tratamiento de la hipertension pulmonar.
MX2013007537A (es) Formulacion farmaceutica que comprende una droga biofarmaceutica.
EP2588106A4 (en) DELAYED RELEASED PHARMACEUTICAL COMPOSITION WITH PRAMIPEXOL OR A PHARMACEUTICALLY ALLOWED SALT AND INCREASED STABILITY
WO2011155793A3 (en) Pharmaceutical composition comprising amide derivative or pharmaceutically acceptable salt thereof
MX2010004211A (es) Composicion oftalmica que comprende una prostaglandina.
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
WO2013055687A3 (en) R(+)-n-formyl-propargyl-aminoindan
WO2012001705A3 (en) Pharmaceutical compositions of (r)-lansoprazole
WO2011163636A3 (en) Compounds and uses thereof in modulating levels of various amyloid beta peptide alloforms
WO2011152809A3 (en) Effervescent formulations comprising cephalosporin and clavulanic acid
WO2014033526A9 (en) Pharmaceutical compositions of etoricoxib
WO2011142731A3 (en) Formulations comprising a third generation cephalosporin and clavulanic acid
MX2016001422A (es) Composicion farmaceutica de fingolimod.
AR089666A1 (es) Formulacion farmaceutica estable para administracion oral que comprende levocetirizina o una de sus sales aceptables desde el punto de vista farmaceutico, y montelukast o una de sus sales aceptables desde el punto de vista farmaceutico
CA2863409A1 (en) N-ethyl-n-phenyl-1,2-dihydro-4,5-di-hydroxy-1-methyl-2-oxo-3-quinolinecarboxamide, preparation and uses thereof
IN2015DN00280A (ko)

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11812698

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11812698

Country of ref document: EP

Kind code of ref document: A2